HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal

  • RnM3875473
  • |
  • 05 February, 2020
  • |
  • 63 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Check Discount on this report



Purchase this Report

$6,995.00
$13,990.00
$20,985.00
5,519.06
11,038.11
16,557.17
6,638.26
13,276.51
19,914.77
1,091,989.45
2,183,978.90
3,275,968.35
590,867.65
1,181,735.30
1,772,602.95
Credit card Logo